IL1B and neoplasm: IL-1β-induced elevation of CRC tumor volume (745.74 ± 188.34) and weight (0.73 ± 0.16) was greatly attenuated by diacerein (619.59 ± 127.03, 0.49 ± 0.09) or nivolumab (540.47 ± 90.92, 0.49 ± 0.10, P < 0.05), and treatment with both drugs led to the greatest attenuation of tumor growth (355.49 ± 39.89, 0.32 ± 0.08, P < 0.001).